USPTO Examiner RAGHU GANAPATHIRAM - Art Unit 1652

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18770533MICROORGANISMS AND METHODS FOR THE CONTINUOUS PRODUCTION OF FATTY ACIDS, FATTY ALCOHOLS, AND CULTURED PROTEIN FROM C1 SUBSTRATESJuly 2024June 2025Abandon1111NoNo
18661739METHOD FOR PRODUCING SCLAREOL BY FERMENTATION OF CIGAR TOBACCO FLOWER BUDSMay 2024October 2024Allow510NoNo
18635214SERINE PROTEASESApril 2024May 2025Allow1300NoNo
18627748METHOD FOR EXTRACTING PULLULAN POLYSACCHARIDE FROM HIGH-VISCOSITY FERMENTATION BROTHApril 2024August 2024Allow510NoNo
18623612METHODS AND COMPOSITIONS FOR MODULATING A GENOMEApril 2024April 2025Allow1301YesNo
18614099KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (R)-3-HYDROXYTHIOLANEMarch 2024April 2025Allow1210YesNo
18437445GLUCOAMYLASE ENGINEERED YEAST AND FERMENTATION METHODSFebruary 2024April 2025Abandon1410NoNo
18435340METHODS FOR MAKING L-GLUFOSINATEFebruary 2024March 2025Allow1410NoNo
18435544METHODS FOR MAKING L-GLUFOSINATEFebruary 2024April 2025Allow1410NoNo
18412090INSECT INHIBITORY TOXIN FAMILY ACTIVE AGAINST HEMIPTERAN AND/OR LEPIDOPTERAN INSECTSJanuary 2024March 2025Abandon1411NoNo
18402680ENGINEERED NUCLEIC ACID-GUIDED NUCLEASESJanuary 2024July 2024Allow610YesNo
18525234UDP-DEPENDENT GLYCOSYLTRANSFERASE FOR HIGH EFFICIENCY PRODUCTION OF REBAUDIOSIDESNovember 2023April 2025Allow1610NoNo
18511394METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVESNovember 2023June 2025Allow1910NoNo
18506648Liquid Cleaning Compositions Comprising Protease VariantsNovember 2023December 2024Allow1410NoNo
18504743Liquid Cleaning Compositions Comprising Protease VariantsNovember 2023December 2024Allow1320YesNo
18496269AUTOMATIC DISHWASHING DETERGENT COMPOSITIONSOctober 2023February 2025Abandon1601NoNo
18384044PRODUCTION OF CAROTENOIDS AND APOCAROTENOIDSOctober 2023April 2025Allow1721YesNo
18485895TUNABLE NANOSCALE CAGES FROM SELF-ASSEMBLING DNA AND PROTEIN BUILDING BLOCKSOctober 2023March 2025Allow1710YesNo
18485501Construction Method and Application of Microorganism Capable of Realizing High Production of Lacto-N-tetroseOctober 2023April 2024Allow610NoNo
18453987METHODS AND ORGANISMS WITH INCREASED CARBON FLUX EFFICIENCIESAugust 2023June 2025Allow2221NoNo
18227147HETEROLOGOUS PRODUCTION OF 10-METHYLSTEARIC ACIDJuly 2023December 2024Abandon1610NoNo
18352899KETOREDUCTASE POLYPEPTIDES AND POLYNUCLEOTIDESJuly 2023November 2024Allow1611NoNo
18339027MICROORGANISMS AND METHODS FOR THE CONTINUOUS CO-PRODUCTION OF HIGH-VALUE, SPECIALIZED PROTEINS AND CHEMICAL PRODUCTS FROM C1-SUBSTRATESJune 2023October 2024Allow1621YesNo
18338242RECOMBINANT OLIVETOLIC ACID CYCLASE POLYPEPTIDES ENGINEERED FOR ENHANCED BIOSYNTHESIS OF CANNABINOIDSJune 2023April 2024Allow1010YesNo
18333776COMPOSITIONS FOR SACCHARIFICATION OF CELLULOSIC MATERIALJune 2023September 2024Allow1510NoNo
18208030PRODUCTION OF ISOPRENOIDSJune 2023July 2024Allow1310NoNo
18327373A UNIVERSAL PLATFORM TO ENHANCE CRISPR-BASED GENE EDITING FOR IN VIVO THERAPIESJune 2023April 2024Allow1101NoNo
18199278METHODS FOR GENOMIC INTEGRATION FOR KLUYVEROMYCES HOST CELLSMay 2023August 2024Allow1510NoNo
18197870COMPOSITIONS AND METHODS INVOLVING ENGINEERED P27May 2023January 2025Allow2021YesNo
18304187Inducible, Tunable, and Multiplex Human Gene Regulation Using CRISPR-Cpf1April 2023September 2024Allow1720NoNo
18301460PROTEASE VARIANTS AND USES THEREOFApril 2023July 2024Allow1510YesNo
18179136METHODS FOR MAKING L-GLUFOSINATEMarch 2023October 2023Allow710NoNo
18040629PRODUCTION OF A MIXTURE OF NEUTRAL NON-FUCOSYLATED OLIGOSACCHARIDES BY A CELLFebruary 2023February 2024Allow1311YesNo
18161236BIOSYNTHESIS OF RETINOIDSJanuary 2023November 2024Allow2211NoNo
18062628BIOSYNTHETIC PRODUCTION OF GAMMA-LACTONESDecember 2022April 2025Allow2811YesNo
18062198Integration Sites in CHO CellsDecember 2022February 2024Allow1400NoNo
18055713LIPID-ENCAPSULATED DUAL-CLEAVING ENDONUCLEASE FOR DNA AND GENE EDITINGNovember 2022August 2023Allow910YesNo
17986618LACTASE ENZYMES WITH IMPROVED PROPERTIESNovember 2022October 2024Allow2311NoNo
17983665PROBIOTIC BACTERIA FOR YEAST BIOETHANOL PRODUCTIONNovember 2022June 2024Allow1910YesNo
18052066Biocementation Method and SystemNovember 2022August 2024Allow2110YesNo
18050245VARIANT AIMOctober 2022August 2024Abandon2210YesNo
17969715AFFINITY TAG FOR RECOMBINATION PROTEIN RECRUITMENTOctober 2022August 2024Abandon2201NoNo
17957218AprL-CLADE PROTEASE VARIANTS AND USES THEREOFSeptember 2022February 2025Allow2910YesNo
17934560PRENYLTRANSFERASE VARIANTS WITH INCREASED THERMOSTABILITYSeptember 2022May 2024Allow1910NoNo
17900590ENZYMES AND APPLICATIONS THEREOFAugust 2022April 2024Allow1910NoNo
17799414PREPARING AND MODIFYING MEROTERPENE POLYKETIDES, KETONES, AND LACTONES FOR CANNABINOID SEMISYNTHESISAugust 2022June 2025Abandon3401NoNo
17882680IMMOBILIZED ENZYME PRODUCTION LINE, METHOD OF MAKING AN IMMOBILIZED ENZYME PRODUCTION LINE, AND METHOD OF MAKING COMPOUNDS USING THE IMMOBILIZED ENZYME PRODUCTION LINEAugust 2022August 2024Abandon2411NoNo
17816892METHODS OF REDUCING ODORAugust 2022July 2023Allow1121YesNo
17816630HETEROLOGOUS BIOSYNTHESIS OF NODULISPORIC ACIDAugust 2022April 2024Allow2001YesNo
17759537Polypeptide VariantsJuly 2022March 2025Allow3201YesNo
17871400METHOD FOR PRODUCING MERCAPTANS BY DISULFIDE ENZYME HYDROGENOLYSISJuly 2022July 2024Abandon2310NoNo
17813950KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (R)-3-HYDROXYTHIOLANEJuly 2022December 2023Allow1710NoNo
17791412METHOD FOR PRODUCING BRANCHED DEXTRIN WITH IMPROVED WHITE TURBIDITYJuly 2022April 2025Allow3410NoNo
17854774Enzyme Variants and Polynucleotides Encoding The SameJune 2022August 2023Allow1411NoNo
17852246COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIAJune 2022June 2024Abandon2310NoNo
17849571MEDIUM COMPOSITION FOR PRODUCING ALCOHOL FROM SYNTHETIC GAS COMPRISING ETHANOL AND METHOD FOR PRODUCING ALCOHOL USING THE SAMEJune 2022December 2023Allow1710NoNo
17846771LIPID-ENCAPSULATED DUAL-CLEAVING ENDONUCLEASE FOR DNA AND GENE EDITINGJune 2022March 2025Allow3320NoNo
17846935METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDSJune 2022August 2024Allow2611YesNo
17845842Yeast Cells and Methods for Producing Fatty AlcoholsJune 2022August 2024Allow2620NoNo
17829416POLYPEPTIDE FOR HYDROLYTIC CLEAVAGE OF ZEARALENONE AND/OR ZEARALENONE DERIVATIVES, ISOLATED POLYNUCLEOTIDE THEREOF AS WELL AS A POLYPEPTIDE CONTAINING AN ADDITIVE, USE OF SAME AS WELL AS A PROCESSJune 2022April 2024Allow2220YesNo
17829431POLYPEPTIDE FOR HYDROLYTIC CLEAVAGE OF ZEARALENONE AND/OR ZEARALENONE DERIVATIVES, ISOLATED POLYNUCLEOTIDE THEREOF AS WELL AS A POLYPEPTIDE CONTAINING AN ADDITIVE, USE OF SAME AS WELL AS A PROCESSJune 2022February 2024Allow2010NoNo
17828457CLASS OF SUCROSE ESTERS AND A METHOD FOR THEIR PREPARATIONMay 2022January 2024Allow2010NoNo
17824118PRENYLTRANSFERASE VARIANTS WITH INCREASED THERMOSTABILITYMay 2022August 2022Allow300YesNo
17804052ENHANCING PRODUCT STREAMS FROM ETHANOL PRODUCTIONMay 2022September 2024Allow2830YesNo
17779967METHOD FOR ENZYMATICALLY PRODUCING MAYTANSINOLMay 2022June 2025Allow3721YesNo
17756400METHODS AND COMPOSITIONS FOR PRODUCING ETHYLENE FROM RECOMBINANT MICROORGANISMSMay 2022May 2025Abandon3501NoNo
17778712CARBONYL REDUCTASE, NUCLEIC ACID ENCODING SAME, AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING SAMEMay 2022July 2025Allow3711YesNo
17750037METHOD FOR PRODUCING JASMONIC ACID BY SOLID STATE FERMENTATION OF MICROORGANISMSMay 2022May 2025Abandon3610NoNo
17778018USE OF CITRONELLOL IN PREPARING PREPARATION FOR PROMOTING EXPRESSION OF VIRULENCE GENE TOXA OF PSEUDOMONAS AERUGINOSAMay 2022September 2023Allow1620YesNo
17745997ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAMEMay 2022February 2024Allow2120YesNo
17746952BACTERIAL TOXINS AND USES THEREOF AS RAS SPECIFIC PROTEASES FOR TREATING CELL PROLIFERATION DISEASES AND DISORDERSMay 2022April 2025Allow3511YesNo
17744773NOVEL PROTEASES AND USES THEREOFMay 2022May 2025Abandon3601NoNo
17776686SQUALENE HOPENE CYCLASE (SHC) VARIANTSMay 2022March 2025Allow3411YesNo
17741763SACCHARIFICATION REACTION MIXTURE, SACCHARIFICATION ENZYME COMPOSITION, SUGAR PRODUCTION METHOD, AND ETHANOL PRODUCTION METHODMay 2022February 2024Allow2111YesNo
17735222POLYPEPTIDE VARIANTSMay 2022June 2024Allow2621NoNo
17734432MYELOID DIFFERENTIATION FACTOR 2 (MD2) SIGNALING AND MODULATIONMay 2022March 2024Allow2320NoNo
17732799Microbial Production Of Fatty DiolsApril 2022October 2024Abandon2911NoNo
17769655ARTIFICIALLY SYNTHESIZED mRNA AND USE OF SAMEApril 2022May 2025Allow3721YesNo
17716348STABILIZED ALPHA-GALACTOSIDASE AND USES THEREOFApril 2022April 2025Allow3620NoYes
17713891OPTIMIZATION OF ENZYME REPLACEMENT THERAPY FOR TREATMENT OF HOMOCYSTINURIAApril 2022March 2024Allow2320NoNo
17657241GLUCOAMYLASE ENGINEERED YEAST AND FERMENTATION METHODSMarch 2022November 2023Allow2020YesNo
17707030PROCESS FOR TREATING LIGNOCELLULOSIC BIOMASSMarch 2022February 2025Allow3541NoNo
17691912Process For Second Generation Lactic Acid ProductionMarch 2022June 2024Allow2720YesNo
17641740GLUCOCEREBROSIDASE MUTANTSMarch 2022February 2025Abandon3510NoNo
17677926THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAMEFebruary 2022March 2024Abandon2511NoNo
17634342NOVEL OLEATE HYDRATASESFebruary 2022February 2025Abandon3601NoNo
17589198Method for fermenting biomass and producing material sheets and suspensions thereofJanuary 2022February 2025Abandon3610NoNo
17631066A Recombinant of Hydrogenophilus Bacterium Producing Lactic AcidJanuary 2022February 2025Allow3711YesNo
17570312Compositions and Methods for Dust ControlJanuary 2022July 2024Allow3120YesNo
17568547INSECT INHIBITORY TOXIN FAMILY ACTIVE AGAINST HEMIPTERAN AND/OR LEPIDOPTERAN INSECTSJanuary 2022October 2023Allow2121NoNo
17621982MODIFIED YEAST AND METHOD FOR INCREASING LYSINE CONTENT IN FERMENTATION CO-PRODUCTSDecember 2021December 2024Allow3611NoNo
17622112PEGYLATED CYSTATHIONINE BETA SYNTHASE FOR ENZYME THERAPY FOR TREATMENT OF HOMOCYSTINURIADecember 2021March 2025Allow3910NoNo
17555731POLYPEPTIDE FOR HYDROLYTIC CLEAVAGE OF ZEARALENONE AND/OR ZEARALENONE DERIVATIVES, ISOLATED POLYNUCLEOTIDE THEREOF AS WELL AS A POLYPEPTIDE CONTAINING AN ADDITIVE, USE OF SAME AS WELL AS A PROCESSDecember 2021October 2023Allow2211NoNo
17554537CELL-FREE PRODUCTION OF GERANYL PYROPHOSPHATE FROM GLYCEROL IN A CELL-FREE MANUFACTURING SYSTEMDecember 2021January 2024Allow2511YesNo
17554278DEHYDRATASE VARIANTS WITH IMPROVED SPECIFIC ACTIVITY FOR THE PRODUCTION OF PYRUVATE FROM GLYCERATEDecember 2021October 2023Allow2220YesNo
17553279USE OF ETHANOLOGENS IN BIOFUEL PRODUCTIONDecember 2021July 2024Allow3130NoNo
17548208RECOMBINANT ACYL ACTIVATING ENZYME (AAE) GENES FOR ENHANCED BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORSDecember 2021May 2024Abandon2921NoNo
17536919NON-CALORIC SWEETENERS AND METHODS FOR SYNTHESIZINGNovember 2021September 2023Allow2101YesNo
17530018METHODS FOR MAKING L-GLUFOSINATENovember 2021October 2023Allow2310NoNo
17454339SYNTHETIC PROMOTER BASED ON GENE FROM ACID-RESISTANT YEASTNovember 2021June 2023Allow1911YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAGHU, GANAPATHIRAM.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
6
(66.7%)
Examiner Reversed
3
(33.3%)
Reversal Percentile
48.4%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
87
Allowed After Appeal Filing
16
(18.4%)
Not Allowed After Appeal Filing
71
(81.6%)
Filing Benefit Percentile
19.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner RAGHU, GANAPATHIRAM - Prosecution Strategy Guide

Executive Summary

Examiner RAGHU, GANAPATHIRAM works in Art Unit 1652 and has examined 1,408 patent applications in our dataset. With an allowance rate of 72.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 26 months.

Allowance Patterns

Examiner RAGHU, GANAPATHIRAM's allowance rate of 72.1% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by RAGHU, GANAPATHIRAM receive 1.64 office actions before reaching final disposition. This places the examiner in the 45% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by RAGHU, GANAPATHIRAM is 26 months. This places the examiner in the 60% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +30.1% benefit to allowance rate for applications examined by RAGHU, GANAPATHIRAM. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 32.2% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 59.1% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 90.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 66% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 81.6% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 80.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 69.8% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.3% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.